首页> 外文期刊>Stem cells international >In Vitro Expansion and Characterization of Mesenchymal Stromal Cells from Peritoneal Dialysis Effluent in a Human Protein Medium
【24h】

In Vitro Expansion and Characterization of Mesenchymal Stromal Cells from Peritoneal Dialysis Effluent in a Human Protein Medium

机译:来自人蛋白质介质中腹膜透析流出物的间充质基质细胞的体外膨胀和表征

获取原文
获取原文并翻译 | 示例
           

摘要

The therapeutic potential of mesenchymal stromal cells (MSCs) from various tissue origins have extensively been explored in both experimental and clinical studies, and peritoneal dialysis effluent-derived MSC (pMSC) may be an easily obtainable MSC source for clinical applications. In this study, we expanded and characterized the pMSCs after expansion in a human protein culture medium. The pMSCs were expanded in plastic dishes with the human protein medium. MSC marker expression was examined by flow cytometry. Spherical formation was tested by hanging drop method, and osteogenic, adipogenic, and chondrogenic differentiation capacities were confirmed by positive staining with Alizarin red, Oil red O, and Alcian blue, respectively. Here, we showed that after four passages of culturing in plastic dishes, pMSCs in the human protein medium displayed a homogeneous pattern of classical MSC markers (positive: CD29, CD44, CD73, CD90, and CD166; negative: CD14, CD34, CD45, CD79a, CD105, CD146, CD271, HLA-DR, SSEA-4, and Stro-1), while in the standard medium, pMSCs from some donors were CD45 or HLA-DR positive. For nonclassical MSC markers, pMSCs were CD200 positive from all the donors, negative for CD163, CD271, CD36, and CD248, and either positive or negative for CD274 and CD140b. Further, pMSCs from the human protein medium had the spherical formation capacity and multipotent differentiation capacity in vitro. In conclusion, upon expansion in a human protein medium, pMSCs showed a differential MSC marker expression profile from those of bone marrow or adipose tissue-derived MSCs and could maintain the multipotency. The therapeutic potential of the pMSCs requires further investigation.
机译:在实验和临床研究中,来自各种组织起源的间充质基质细胞(MSCs)的治疗潜力在实验和临床研究中探讨了,并且腹膜透析流出物衍生的MSC(PMSC)可以是临床应用的可容易获得的MSC源。在这项研究中,我们在人蛋白培养基中扩增后扩展和表征了PMSCs。用人蛋白质培养基将PMSC膨胀在塑料盘中。通过流式细胞术检查MSC标记表达。通过悬垂的方法测试球形形成,并通过分别用茜素红,油红色O和Alcian蓝的阳性染色来确认骨质发生,脂肪发生和软骨形成分化能力。在这里,我们表明,在塑料盘中培养的四次介绍后,人蛋白质中的PMSC显示出典型MSC标记的均匀模式(阳性:CD29,CD44,CD73,CD90和CD166;阴性:CD14,CD34,CD45, CD79A,CD105,CD146,CD271,HLA-DR,SSEA-4和Stro-1),而在标准介质中,来自一些供体的PMSCs是CD45或HLA-DR阳性。对于非核化MSC标记物,PMSCS是来自所有供体的CD200阳性,CD163,CD271,CD36和CD248负,对CD274和CD140B的阳性或阴性。此外,来自人蛋白质培养基的PMSCs在体外具有球形形成能力和多能分化能力。总之,在人蛋白质培养基中的膨胀后,PMSC显示骨髓或脂肪组织衍生的MSCs的差异MSC标记表达谱,并且可以保持多能。 PMSC的治疗潜力需要进一步调查。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号